Cargando…

The NeuroAiD Safe Treatment (NeST) Registry: a protocol

INTRODUCTION: NeuroAiD (MLC601, MLC901), a combination of natural products, has been shown to be safe and to aid neurological recovery after brain injuries. The NeuroAiD Safe Treatment (NeST) Registry aims to assess its use and safety in the real-world setting. METHODS AND ANALYSIS: The NeST Registr...

Descripción completa

Detalles Bibliográficos
Autores principales: Venketasubramanian, Narayanaswamy, Kumar, Ramesh, Soertidewi, Lyna, Abu Bakar, Azizi, Laik, Carine, Gan, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4654343/
https://www.ncbi.nlm.nih.gov/pubmed/26567259
http://dx.doi.org/10.1136/bmjopen-2015-009866
_version_ 1782402042522763264
author Venketasubramanian, Narayanaswamy
Kumar, Ramesh
Soertidewi, Lyna
Abu Bakar, Azizi
Laik, Carine
Gan, Robert
author_facet Venketasubramanian, Narayanaswamy
Kumar, Ramesh
Soertidewi, Lyna
Abu Bakar, Azizi
Laik, Carine
Gan, Robert
author_sort Venketasubramanian, Narayanaswamy
collection PubMed
description INTRODUCTION: NeuroAiD (MLC601, MLC901), a combination of natural products, has been shown to be safe and to aid neurological recovery after brain injuries. The NeuroAiD Safe Treatment (NeST) Registry aims to assess its use and safety in the real-world setting. METHODS AND ANALYSIS: The NeST Registry is designed as a product registry that would provide information on the use and safety of NeuroAiD in clinical practice. An online NeST Registry was set up to allow easy entry and retrieval of essential information including demographics, medical conditions, clinical assessments of neurological, functional and cognitive state, compliance, concomitant medications, and side effects, if any, among patients on NeuroAiD. Patients who are taking or have been prescribed NeuroAiD may be included. Participation is voluntary. Data collected are similar to information obtained during standard care and are prospectively entered by the participating physicians at baseline (before initialisation of NeuroAiD) and during subsequent visits. The primary outcome assessed is safety (ie, non-serious and serious adverse event), while compliance and neurological status over time are secondary outcomes. The in-person follow-up assessments are timed with clinical appointments. Anonymised data will be extracted and collectively analysed. Initial target sample size for the registry is 2000. Analysis will be performed after every 500 participants entered with completed follow-up information. ETHICS AND DISSEMINATION: Doctors who prescribe NeuroAiD will be introduced to the registry by local partners. The central coordinator of the registry will discuss the protocol and requirements for implementation with doctors who show interest. Currently, the registry has been approved by the Ethics Committees of Universiti Kebangsaan Malaysia (Malaysia) and National Brain Center (Indonesia). In addition, for other countries, Ethics Committee approval will be obtained in accordance with local requirements. TRIAL REGISTRATION NUMBER: NCT02536079.
format Online
Article
Text
id pubmed-4654343
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-46543432015-12-02 The NeuroAiD Safe Treatment (NeST) Registry: a protocol Venketasubramanian, Narayanaswamy Kumar, Ramesh Soertidewi, Lyna Abu Bakar, Azizi Laik, Carine Gan, Robert BMJ Open Neurology INTRODUCTION: NeuroAiD (MLC601, MLC901), a combination of natural products, has been shown to be safe and to aid neurological recovery after brain injuries. The NeuroAiD Safe Treatment (NeST) Registry aims to assess its use and safety in the real-world setting. METHODS AND ANALYSIS: The NeST Registry is designed as a product registry that would provide information on the use and safety of NeuroAiD in clinical practice. An online NeST Registry was set up to allow easy entry and retrieval of essential information including demographics, medical conditions, clinical assessments of neurological, functional and cognitive state, compliance, concomitant medications, and side effects, if any, among patients on NeuroAiD. Patients who are taking or have been prescribed NeuroAiD may be included. Participation is voluntary. Data collected are similar to information obtained during standard care and are prospectively entered by the participating physicians at baseline (before initialisation of NeuroAiD) and during subsequent visits. The primary outcome assessed is safety (ie, non-serious and serious adverse event), while compliance and neurological status over time are secondary outcomes. The in-person follow-up assessments are timed with clinical appointments. Anonymised data will be extracted and collectively analysed. Initial target sample size for the registry is 2000. Analysis will be performed after every 500 participants entered with completed follow-up information. ETHICS AND DISSEMINATION: Doctors who prescribe NeuroAiD will be introduced to the registry by local partners. The central coordinator of the registry will discuss the protocol and requirements for implementation with doctors who show interest. Currently, the registry has been approved by the Ethics Committees of Universiti Kebangsaan Malaysia (Malaysia) and National Brain Center (Indonesia). In addition, for other countries, Ethics Committee approval will be obtained in accordance with local requirements. TRIAL REGISTRATION NUMBER: NCT02536079. BMJ Publishing Group 2015-11-13 /pmc/articles/PMC4654343/ /pubmed/26567259 http://dx.doi.org/10.1136/bmjopen-2015-009866 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Neurology
Venketasubramanian, Narayanaswamy
Kumar, Ramesh
Soertidewi, Lyna
Abu Bakar, Azizi
Laik, Carine
Gan, Robert
The NeuroAiD Safe Treatment (NeST) Registry: a protocol
title The NeuroAiD Safe Treatment (NeST) Registry: a protocol
title_full The NeuroAiD Safe Treatment (NeST) Registry: a protocol
title_fullStr The NeuroAiD Safe Treatment (NeST) Registry: a protocol
title_full_unstemmed The NeuroAiD Safe Treatment (NeST) Registry: a protocol
title_short The NeuroAiD Safe Treatment (NeST) Registry: a protocol
title_sort neuroaid safe treatment (nest) registry: a protocol
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4654343/
https://www.ncbi.nlm.nih.gov/pubmed/26567259
http://dx.doi.org/10.1136/bmjopen-2015-009866
work_keys_str_mv AT venketasubramaniannarayanaswamy theneuroaidsafetreatmentnestregistryaprotocol
AT kumarramesh theneuroaidsafetreatmentnestregistryaprotocol
AT soertidewilyna theneuroaidsafetreatmentnestregistryaprotocol
AT abubakarazizi theneuroaidsafetreatmentnestregistryaprotocol
AT laikcarine theneuroaidsafetreatmentnestregistryaprotocol
AT ganrobert theneuroaidsafetreatmentnestregistryaprotocol
AT venketasubramaniannarayanaswamy neuroaidsafetreatmentnestregistryaprotocol
AT kumarramesh neuroaidsafetreatmentnestregistryaprotocol
AT soertidewilyna neuroaidsafetreatmentnestregistryaprotocol
AT abubakarazizi neuroaidsafetreatmentnestregistryaprotocol
AT laikcarine neuroaidsafetreatmentnestregistryaprotocol
AT ganrobert neuroaidsafetreatmentnestregistryaprotocol